Skip to main content
. Author manuscript; available in PMC: 2017 Feb 28.
Published in final edited form as: Thromb Haemost. 2015 Oct 15;115(3):551–561. doi: 10.1160/TH15-07-0525

Figure 6. Combination therapy with superFVa and rhFVIIa enhances bleed correction in FVIII-deficient mice.

Figure 6

FVIII-deficient mice were injected intravenously with saline, rhFVIII, increasing doses of superFVa or rhFVIIa, as well as rhFVIIa in combination with superFVa. Bleeding was determined during 20 minutes after tail clip and expressed as Tl blood loss per gram mouse. A) Dose responses of bleed correction by either superFVa or rhFVIIa in comparison to untreated and FVIII treated FVIII-deficient mice. These conditions provide the reference points for the evaluation of efficacy of superFVa and rhFVIIa combinations in panels (B) and (C). B) Cooperation of “low” doses of superFVa (10 U/kg) and rhFVIIa (1 mg/kg) to reduce bleeding in FVIII-deficient mice. C) Cooperation of a “medium” dose of superFVa (40 U/kg) and rhFVIIa (3 mg/kg) to reduce bleeding in FVIII-deficient mice. Note: the open circles in panels (B) and (C) are the single-agent controls derived from the dose response in panel (A). Error bars represent mean ± SEM (n = 8–12 as indicated). 1 Unit superFVa = activity of 20 nM wild-type FVa in the prothrombinase assay. * p≤ 0.05; ** p≤ 0.005; *** p≤ 0.0005.